Advertisement

Intraperitoneal Chemotherapy with Mitomycin C or Cisplatin

  • Masahiro Hiratsuka
  • Hiroshi Furukawa
  • Takushi Yasuda
  • Kohei Murata
  • Terumasa Yamada
  • Hiroaki Ohigashi
  • Masao Kameyama
  • Yo Sasaki
  • Toshiyuki Kabuto
  • Osamu Ishikawa
  • Shingi Imaoka

Abstract

Intraperitoneal dissemination is a frequently observed form of recurrence after gastric cancer surgery. It has been reported that positivity of a cytological examination of free cancer cells in the peritoneal cavity after curative resection of gastric cancer is as high as 16%, and all the patients with positive cytological results died within 5 years after the surgery [1].The most important merit of intraperitoneal (i.p.) chemotherapy lies in that a much higher drug concentration in the peritoneal cavity can be achieved compared with that achieved with intravenous (i.v.) chemotherapy [2, 3, 4, 5].

Keywords

Gastric Cancer Methylene Blue Clin Oncol Gastric Cancer Patient Advanced Gastric Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Nakajima T, Harashima S, Hirata M, Kajitani T (1978) Prognostic and therapeutic values of peritoneal cytology in gastric cancer. Acta Cytol 22:225–229PubMedGoogle Scholar
  2. 2.
    Dedrick RL, Myers CE, Bungay PM, DeVita VT (1978) Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62:1–11PubMedGoogle Scholar
  3. 3.
    Casper ES, Kelsen DP, Alcock NW, Lewis JL (1983) IP cisplatin in patients with malignant ascites: pharmacokinetic evaluation and comparison with the iv route. Cancer Treat Rep 67:235–238PubMedGoogle Scholar
  4. 4.
    Howell SB, Pfeifle CE, Wung WE, Olshen RA (1983) Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection. Cancer Res 43:1426–1431PubMedGoogle Scholar
  5. 5.
    Reichman B, Markman M, Hakes T, Kemeny N, Kelsen D, Hoskins W, Rubin S, Lewis JL (1988) Phase I trial of concurrent intraperitoneal and continuous intravenous infusion of Fluorouracil in patients with refractory cancer. J Clin Oncol 6:158–162PubMedGoogle Scholar
  6. 6.
    Hermans J, Bonenkamp JJ, Boon MC, Bunt AMG, Ohyama S, Sasako M, Van de Velde CJH (1993) Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 11:1441–1447PubMedGoogle Scholar
  7. 7.
    MacDonald JS, Woolley PV, Smythe T, Ueno W, Hoth D, Schein PS (1979) 5-Fluorouracil, Adriamycin, and mitomycin C (FAM) combination chemotherapy in the treatment of advanced gastric cancer. Cancer 44:42–47PubMedCrossRefGoogle Scholar
  8. 8.
    Gastrointestinal Tumor Study Group (1982) A comparative clinical assessment of combination chemotherapy in the management of advanced gastric carcinoma. Cancer 49:1362–1366CrossRefGoogle Scholar
  9. 9.
    Hagiwara A, Takahashi T, Kojima O, Sawai K, Yamaguchi T, Yamane T, Taniguchi H, Kitamura K, Noguchi A, Seiki K, Sakakura C (1992) Prophylaxis with carbon-adsorbed mitomycin against peritoneal recurrence of gastric cancer. Lancet 339:629–631PubMedCrossRefGoogle Scholar
  10. 10.
    Hiratsuka M, Ogawa A, Ohigashi H, Kameyama M, Sasaki Y, Ishikawa O, Kabuto T, Fukuda I, Furukawa H, Imaoka S, Koyama H, Iwanaga T (1988) Dosage and its safety on intraperitoneal high dose mitomycin C administration as postoperative adjuvant therapy for gastric cancer. J Jpn Soc Cancer Ther 23:1574–1579Google Scholar
  11. 11.
    Howell SB, Kirmani S, Lucas WE, Zimm S, Goel R, Kim S, Horton MC, McVey L, Morris J, Weiss RJ (1990) A phase II trial of intraperitoneal cisplatin and etoposide for primary treatment of ovarian epithelial cancer. J Clin Oncol 8:137–145PubMedGoogle Scholar
  12. 12.
    Schilsky RL, Choi KE, Grayhack J, Grimmer D, Guarnieri C, Fullern L (1990) Phase I clinical and pharmacologic study of intraperitoneal cisplatin and fluorouracil in patients with advanced intraabdominal cancer. J Clin Oncol 8:2054–2061PubMedGoogle Scholar
  13. 13.
    Leichman L, McDonald B, Dindogru A, Samson M, Vaitkevicius VK (1984) An active drug in the treatment of disseminated gastric cancer. Cancer 53:18–22PubMedCrossRefGoogle Scholar
  14. 14.
    Tsujitani S, Okuyama T, Watanabe A, Abe Y, Maehara Y, Sugimachi K (1993) Intraperitoneal cisplatin during surgery for gastric cancer and peritoneal seeding. Anticancer Res 13:1831–1834PubMedGoogle Scholar
  15. 15.
    Sautner T, Hofbauer F, Depisch D, Schiessel R, Jackesz R (1994) Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer. J Clin Oncol 12:970–974PubMedGoogle Scholar
  16. 16.
    Hiratsuka M, Furukawa H, Iwanaga T, Nakamori S, Masutani S, Ohigashi H, Kameyama M, Sasaki Y, Kabuto T, Ishikawa O, Koyama H, Imaoka S (1993) Pharmacokinetics following intraperitoneal sequential administration of cisplatin and fluorouracil for gastric cancer. Jpn J Cancer Chemother 20:1627–1630Google Scholar
  17. 17.
    Japanese Research Society for Gastric Cancer (1995) Japanese classification of gastric carcinoma, 1st English edition. Kanehara, TokyoGoogle Scholar
  18. 18.
    Kitamura M, Furukawa H, Kito T, Nashimoto A, Kunii Y, Okabayashi K, Nakajima T, Fukushima M, Yanagawa T (1995) Chemosensitivity of gastric cancer using adhesive tumor cell culture system. Oncol Rep 2:27–31PubMedGoogle Scholar
  19. 19.
    Hiratsuka M, Furukawa H, Iwanaga T, Tamura S, Yasuda T, Nakamori S, Ohigashi H, Kameyama M, Sasaki Y, Kabuto T, Ishikawa O, Imaoka S (1998) Peritoneal lavage cytology and intraperitoneal chemotherapy. In: Yonemura Y (ed) Peritoneal dissemination: molecular mechanisms and the latest therapy. Maeda Shoten, Kanazawa, Japan, pp 201–214Google Scholar
  20. 20.
    Yu W, Whang I, Suh I, Averbach A, Chang D, Sugarbaker PH (1998) Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg 228:347–354PubMedCrossRefGoogle Scholar
  21. 21.
    Rosen HR, Jatzko G, Repse S, Potrc S, Neudorfer H, Sandbichler P, Zacherl J, Rabl H, Holzberger P, Lisborg P, Czeijka M (1998) Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian working group for surgical oncology. J Clin Oncol 16:2733–2738PubMedGoogle Scholar
  22. 22.
    Hiratsuka M, Furukawa H, Yasuda T, Murata K, Nakano H, Ohigashi H, Kameyama M, Sasaki Y, Kabuto T, Ishikawa O, Imaoka S (1998) Report of case who survived more than five years after repeated intraperitoneal chemotherapy with cisplatin and 5-fluorouracil for treatment of macroscopically negative but microscopically positive peritoneal dissemination of gastric cancer. Jpn J Cancer Chemother 25:1445–1448Google Scholar
  23. 23.
    Atiq OT, Kelsen DP, Shiu MH, Saltz L, Tong W, Niedzwiecki D, Trochanowski B, Lin S, Toomasi F, Brennan M (1993) Phase II trial of postoperative adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancer. J Clin Oncol 11:425–433PubMedGoogle Scholar
  24. 24.
    Crookes P, Leichman CG, Leichman L, Tan M, Laine L, Stain S, Baranda J, Casagrande Y, Groshen S, Silberman H (1997) Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy: a final report. Cancer 79:1767–1775PubMedCrossRefGoogle Scholar
  25. 25.
    Sugarbaker PH, Graves T, DeBruinjn EA, Cunliffe WJ, Mullins RE, Hull WE, Oliff L, Schlag P (1990) Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacological studies. Cancer Res 50:5790–5794PubMedGoogle Scholar
  26. 26.
    Kelsen D, Karpeh M, Schwartz G, Gerdes H, Lightdale C, Botet J, Lauers G, Klimstra D, Huang Y, Saltz L, Quan V, Brennan M (1996) Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil. J Clin Oncol 14:1818–1828PubMedGoogle Scholar
  27. 27.
    Adachi W, Koike S, Rafique M, Kajikawa S, Kaneko G, Kuroda T, Iida F, Ishii K (1995) Preoperative intraperitoneal chemotherapy for gastric cancer, with special reference to delayed peritoneal complications. Surg Today 25:396–403PubMedCrossRefGoogle Scholar
  28. 28.
    Galili Y, Abraham RB, Rabau M, Klausner J, Klugar Y (1998) Reduction of surgery-induced peritoneal adhesions by methylene blue. Am J Surg 175:30–32PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 1999

Authors and Affiliations

  • Masahiro Hiratsuka
    • 1
  • Hiroshi Furukawa
    • 1
  • Takushi Yasuda
    • 1
  • Kohei Murata
    • 1
  • Terumasa Yamada
    • 1
  • Hiroaki Ohigashi
    • 1
  • Masao Kameyama
    • 1
  • Yo Sasaki
    • 1
  • Toshiyuki Kabuto
    • 1
  • Osamu Ishikawa
    • 1
  • Shingi Imaoka
    • 1
  1. 1.Department of SurgeryOsaka Medical Center for Cancer and Cardiovascular DiseasesOsakaJapan

Personalised recommendations